Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.

Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.

Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.

Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.

The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.

Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.

De K/W-verhouding kan momenteel niet worden berekend voor Vertex Pharmaceuticals.

De KUV kan momenteel niet worden berekend voor Vertex Pharmaceuticals.

De AlleAktien Qualitätsscore kan momenteel niet berekend worden voor Vertex Pharmaceuticals.

De omzet kan momenteel niet worden berekend voor Vertex Pharmaceuticals.

De winst kan momenteel niet berekend worden voor Vertex Pharmaceuticals.

Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.

Vertex Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Vertex Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Vertex Pharmaceuticals is US92532F1003.

Het WKN van Vertex Pharmaceuticals is 882807.

De ticker van Vertex Pharmaceuticals is VRTX.

Binnen de laatste 12 maanden betaalde Vertex Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Vertex Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Vertex Pharmaceuticals is momenteel .

Vertex Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Vertex Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Vertex Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Vertex Pharmaceuticals van 3-1-2025 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 3-1-2025 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 3-1-2025.

In het jaar 2024 heeft Vertex Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Vertex Pharmaceuticals worden in USD uitgekeerd.